Sclerosis multiplex (SM): vizsgálatok itt: Csehország
22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- Where
- Brno, Brno-Stred, Choceň, Hradec Králové, Olomouc, Teplice
- Életkor
- 18 év to 60 év
- People
- 705 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00 - 3. fázisTaking peopleA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Where
- Brno, Choceň, Hradec Králové, Jihlava 1, Olomouc, Ostrava, Prague, Zlin
- Életkor
- 18 év to 60 év
- People
- 990 worldwide
- Run by
- Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00 - 2. fázisTaking peopleStudy to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
- Where
- Brno-Stred, Hradec Králové, Pardubice, Prague 2, Prague 4, Teplice, Zlin
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Celgene Corp.
See details and how to join2024-517745-14-00 · EU 2024-517745-14-00 - No phaseTaking peopleNon-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
- Where
- Pardubice
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07827586 - 3. fázisTaking peopleEfficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
- Where
- Brno-Stred, Jihlava 1, Novy Hradec Kralove, Pardubice, Zlin
- Életkor
- 18 év to 64 év
- People
- 386 worldwide
- Run by
- Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Where
- Brno, Hradec Králové, Pardubice, Prague, Teplice, Zlín
- Életkor
- 18 év to 70 év
- People
- 200 worldwide
- Run by
- Celgene
See details and how to joinNCT06782490 - 3. fázisTaking peopleEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Where
- Brno, Brno-Stred, Hradec Králové, Jihlava 1, Pardubice, Prague
- Életkor
- 40 év to 70 év
- People
- 400 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06846281 · EU 2023-509275-17-00 - 2. fázisTaking peopleMulticenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
- Where
- Novy Hradec Kralove, Teplice
- Életkor
- 18 év to 64 év
- People
- 230 worldwide
- Run by
- Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00 - 3. fázisTaking peopleA Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
- Where
- Brno-Stred, Hradec Kralove, Jihlava 1, Novy Hradec Kralove, Teplice
- Életkor
- 18 év to 64 év
- People
- 125 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Where
- Brno, Hradec Králové, Jihlava, Prague, Teplice
- Életkor
- 18 év to 65 év
- People
- 1275 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07225504 - 3. fázisTaking peopleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Where
- Brno, Brno-Stred, Hradec Králové, Jihlava 1, Ostrava, Pardubice, Prague, Prague 2, Teplice, Zlin
- Életkor
- 18 év to 60 év
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07325292 · EU 2026-525688-41-00 - No phaseTaking peopleEarly Detection of Selected Neuropathologies in Motor Vehicle Drivers
- Where
- Olomouc
- Életkor
- 18 év to 85 év
- People
- 200
- Run by
- University Hospital Olomouc
See details and how to joinNCT07360886 - 2. fázisTaking peopleA Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis
- Where
- Brno-Stred, Jihlava 1, Prague 2
- Életkor
- 18 év to 64 év
- People
- 93 worldwide
- Run by
- Zenas Biopharma (USA) LLC
See details and how to join2024-512707-40-00 · EU 2024-512707-40-00 - 3. fázisTaking peopleA clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
- Where
- Brno-Stred, Hradec Králové, Jihlava 1, Prague, Teplice
- Életkor
- 18 év and over
- People
- 677 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00 - No phaseNot yet taking people in CsehországComprehensive Rehabilitation Programme in People With Multiple Sclerosis: The RECONNECT-MS Study
- Where
- Prague
- Életkor
- 18 év to 65 év
- People
- 45
- Run by
- Charles University, Czech Republic
See details and how to joinNCT07666958 - 1. fázisNot yet taking people in CsehországA Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus
- Where
- Hradec Králové, Jihlava 1, Olomouc, Teplice, Zlin
- Életkor
- 18 év to 65 év
- People
- 222 worldwide
- Run by
- Polpharma Biologics International AG
See details and how to joinNCT07606521 · EU 2026-525314-61-00 - 2. fázisTaking peoplePsilocybin Therapy for Psychological Distress in Palliative Patients
- Where
- Klecany
- Életkor
- 18 év and over
- People
- 108 worldwide
- Run by
- University Medical Center Groningen
See details and how to joinNCT06782724 · EU 2023-510488-36-01 - No phaseTaking peopleClinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
- Where
- Prague
- Életkor
- 18 év and over
- People
- 7000 worldwide
- Run by
- icometrix
See details and how to joinNCT06280755 - No phaseCsak meghívásosClinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
- Where
- Prague
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- icometrix
See details and how to joinNCT07032246 - No phaseNot yet taking people in CsehországComprehensive Therapeutic Program For People With Multiple Sclerosis
- Where
- Prague
- Életkor
- Up to 75 év
- People
- 26
- Run by
- Charles University, Czech Republic
See details and how to joinNCT07248657 - 4. fázisTaking peopleThe use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
- Where
- Ostrava
- Életkor
- 18 év and over
- People
- 100
- Run by
- Fakultni Nemocnice Ostrava
See details and how to join2024-514549-12-00 · EU 2024-514549-12-00 - No phaseTaking peopleThe Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related to QoL in MS Patients
- Where
- Ostrava
- Életkor
- 18 év and over
- People
- 40
- Run by
- University Hospital Ostrava
See details and how to joinNCT06218927